跳至主要内容
临床试验/NCT02210156
NCT02210156已完成不适用

Effects of a Dietary Supplement on the Incidence of Acute Respiratory Infections in Susceptible Adults

Omnilife Manufactura, SA de CV2 个研究点 分布在 1 个国家目标入组 45 人开始时间: 2012年1月1日最近更新:
适应症

试验速览

阶段
不适用
状态
已完成
发起方
入组人数
45
试验地点
2
主要终点
Incidence of acute respiratory infections

研究概览

简要总结

The purpose of this study is to determine whether the consumption of a nutritional supplement with micronutrients and herbal extracts has an effect on the incidence of acute respiratory infections in susceptible adults.

Our hypothesis is that subjects who consume the nutritional supplement will have a lower incidence and duration of acute respiratory infections in comparison with the placebo group.

详细描述

We conducted a randomized, parallel, double-blind, placebo-controlled, 90-day clinical trial from January to April, 2012. All staff who worked at the Omnilife's Entrepreneur Support Department (CREO by its initials in Spanish) were invited to participate. This department within Omnilife has a high incidence of acute respiratory infections (ARI) as reported internally by the company's medical service (accounting for 55% of doctor visits within the department in 2010) and hence, they represent a high number of individuals susceptible to ARI.

We held a preliminary session with the department's entire staff to explain the procedures; we asked subjects interested to participate in the study to sign an informed consent form and fill a clinical history. The latter included an assessment of stress, using the Perceived Stress Scale (in which higher scores indicate higher levels of stress), and physical activity, using the International Physical Activity Questionnaire or IPAQ (in which physical activity is categorized in three levels: light, moderate and vigorous).

In a second session the same week, participants visited the company's medical service for measurements of their weight and height (in accordance with the International Society for the Advancement of Kinanthropometry or ISAK standards), control laboratory tests and a medical examination to rule out the presence of infections. Weight measurements were taken using a Tanita BC553 Ironman Inner Scan Body Fat Scale (capacity of 150 kg, accuracy to 0.1 kg). Height measurements were made using a Seca 206 Stadiometer (accuracy to 0.1 cm, measuring range to 220 cm). Both measurements were performed by a two certified and standardized anthropometrists. Body mass index (BMI) was subsequently calculated using both variables as follows: BMI = weight in kg/(height in m)2.

The medical examination was performed by the attending physician and a nurse. It consisted of an assessment of vital signs following procedures described in the literature and a physical examination of bodily organs and systems. Temperature was measured using a Microlife MT 1931 digital thermometer (measuring range from 32 to 43.9°C, accuracy to 0.1°C). Heart and respiratory rates were measured using a 3M Littmann Classic II S.E. stethoscope. Blood pressure readings were taken using a 3M Littmann Classic II S.E. stethoscope and an Aneroid Sphygmomanometer ce0483 (18-300 mmHg measurement range, accuracy to 2 mmHg).

Laboratory tests were conducted with the support of an external laboratory (Instituto Diagnostico Especializado Arboledas, IDEA by its initials in Spanish). Included were a blood test of six items (fasting glucose, uric acid, creatinine, blood urea nitrogen, cholesterol and triglycerides) analyzed by the spectrophotometric method, a complete blood count with a flow cytometry/microscopy analysis of platelets, and a spectroscopy analysis to assess liver function. Subjects of laboratory analyses were tested after a 12-hour fast. This laboratory has obtained quality control certification from the Quality Assurance for Laboratories Program (PACAL) and the Internal Evaluation Quality Program (PREVECAL). In addition, its staff is certified in clinical diagnosis by the National Association of Clinical Chemists (CONAQUIC).

研究设计

研究类型
Interventional
分配方式
Randomized
干预模型
Parallel
主要目的
Prevention
盲法
Double (Participant, Outcomes Assessor)

入排标准

年龄范围
18 Years 至 60 Years(Adult)
性别
All
接受健康志愿者

入选标准

  • Healthy adult subjects (without active respiratory infections, or without diseases that compromise immune system)
  • Who presented no abnormalities in their laboratory tests (active infections, immunosuppression, renal or hepatic impairment)
  • Who did not take drugs that affect the immune system (anti-inflammatory drugs, antibiotics, steroids).

排除标准

  • Subjects with active acute respiratory infections.
  • Subjects with chronic respiratory disease requiring treatment other than bronchodilators at the time of assessment.
  • Subjects with diseases affecting the immune system (autoimmune illness, diabetes, etc.)
  • Pregnant women or currently nursing.
  • Subjects with cardiovascular disorders (uncontrolled hypertension) or neurological disorders (epilepsy).
  • Subjects with allergies to any components of the products.
  • Subjects with low treatment adherence (less than 80%).

结局指标

主要结局

Incidence of acute respiratory infections

时间窗: 90 days

Number of subjects with at least one episode of acute respiratory infection according to supplementation group.

次要结局

  • Blood urea nitrogen(90 days)
  • Creatinine(90 days)
  • Mean episodes of acute respiratory infections(90 days)
  • Episode-related medication(90 days)
  • Fasting glucose(90 days)
  • Uric acid(90 days)
  • Mean duration of acute respiratory infections(90 days)
  • Number of subjects with more than one acute respiratory infection episode(90 days)
  • Number of acute respiratory infections(90 days)
  • Triglycerides(90 days)
  • Absenteeism(90 days)
  • Cholesterol(90 days)

研究者

发起方
Omnilife Manufactura, SA de CV
申办方类型
Industry
责任方
Sponsor

研究点 (2)

Loading locations...

相似试验

Effects of a Supplement on Acute Respiratory... | 临床试验